Fig. 5: ctDNA monitoring: defining molecular progression. | npj Breast Cancer

Fig. 5: ctDNA monitoring: defining molecular progression.

From: Personalized ctDNA monitoring in metastatic HR+/HER2− breast cancer patients during endocrine and CDK4/6 inhibitor therapy

Fig. 5

a ctDNA dynamics over time and different exploratory definitions of molecular progression. b Test performance of different definitions of molecular progression. Performance characteristics were analyzed comparing matched on-treatment ctDNA timepoints and restaging CT scans, where the time interval between them could be up to +/−30 days. Se sensitivity, Sp specificity, PPV positive predictive value, NPV negative predictive value, Acc accuracy, Pro proportion.

Back to article page